A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine

Journal of Virology

Volumn 82, Issue 17, 2008, Pages 8431-8441

  Brittle, Elizabeth E ^a   Wang, Fushan ^a   Lubinski, John M ^a   Bunte, Ralph M ^b   Friedman, Harvey M ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERPES SIMPLEX VACCINE; LIVE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; IMMUNITY; INOCULATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPINAL GANGLION; VAGINA; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ADOLESCENT; ANIMALS; CHILD; DEFECTIVE VIRUSES; FEMALE; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HUMANS; IMMUNIZATION, SECONDARY; MICE; MICE, INBRED BALB C; VACCINES, ATTENUATED; VIRUS REPLICATION;

HERPES; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS; MUS; SIMPLEXVIRUS;

EID: 50149109604     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00551-08     Document Type: Article

References (44)

1. Awasthi, S., J. M. Lubinski, R. J. Eisenberg, G. H. Cohen, and H. M. Friedman. 2008. An HSV-1 gD mutant virus as an entry-impaired live virus vaccine. Vaccine 26:1195-1203.
2. Barr, E., and G. Tamms. 2007. Quadrivalent human papillomavirus vaccine. Clin. Infect. Dis. 45:609-617.
3. Basu, S., G. Dubin, M. Basu, V. Nguyen, and H. M. Friedman. 1995. Characterization of regions of herpes simplex virus type 1 glycoprotein E involved in binding the Fc domain of monomeric IgG and in forming a complex with glycoprotein I. J. Immunol. 154:260-267.
4. Bernstein, D. I., F. Y. Aoki, S. K. Tyring, L. R. Stanberry, C. St-Pierre, S. D. Shafran, G. Leroux-Roels, K. Van Herck, A. Bollaerts, and G. Dubin. 2005. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin. Infect. Dis. 40:1271-1281.
5. Blacklaws, B. A., S. Krishna, A. C. Minson, and A. A. Nash. 1990. Immunogenicity of herpes simplex virus type 1 glycoproteins expressed in vaccinia virus recombinants. Virology 177:727-736.
6. Brittle, E. E., A. E. Reynolds, and L. W. Enquist. 2004. Two modes of pseudorabies virus neuroinvasion and lethality in mice. J. Virol. 78:12951-12963.
7. Brown, E. L., A. Wald, J. P. Hughes, R. A. Morrow, E. Krantz, K. Mayer, S. Buchbinder, B. Kohlin, and C. Celum. 2006. High risk of human immunodeficiency virus in men who have sex with men with herpes simplex virus type 2 in the EXPLORE study. Am. J. Epidemiol. 164:733-741.
8. Ch'ng, T. H., and L. W. Enquist. 2005. Efficient axonal localization of alphaherpesvirus structural proteins in cultured sympathetic neurons requires viral glycoprotein E. J. Virol. 79:8835-8846.
9. Da Costa, X., M. F. Kramer, J. Zhu, M. A. Brockman, and D. M. Knipe. 2000. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J. Virol. 74:7963-7971.
10. de Bruyn, G., M. Vargas-Cortez, T. Warren, S. K. Tyring, K. H. Fife, J. Lalezari, R. C. Brady, M. Shahmanesh, G. Kinghorn, and K. R. Beutner. 2006. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24:914-920.
11. Dingwell, K. S., C. R. Brunetti, R. L. Hendricks, Q. Tang, M. Tang, A. J. Rainbow, and D. C. Johnson. 1994. Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. J. Virol. 68:834-845.
12. Dubin, G., E. Socolof, I. Frank, and H. M. Friedman. 1991. Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J. Virol. 65:7046-7050.
13. Durmanova, V., T. Mosko, M. Sapak, J. Kosovsky, I. Rezuchova, M. Buc, and J. Rajcani. 2006. Efficacy of recombinant herpes simplex virus 1 glycoprotein D candidate vaccines in mice. Acta Microbiol. Immunol. Hung. 53:459-477.
14. Friedman, H. M. 2006. Keratin, a dual role in herpes simplex virus pathogenesis. J. Clin. Virol. 35:103-105.
15. Friedman, H. M., E. J. Macarak, R. R. MacGregor, J. Wolfe, and N. A. Kefalides. 1981. Virus infection of endothelial cells. J. Infect. Dis. 143:266-273.
16. Ghiasi, H., R. Kaiwar, A. B. Nesburn, S. Slanina, and S. L. Wechsler. 1994. Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. J. Virol. 68:2118-2126.
17. Harris, S. L., I. Frank, A. Yee, G. H. Cohen, R. J. Eisenberg, and H. M. Friedman. 1990. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J. Infect. Dis. 162:331-337.
18. Holmberg, S. D., J. A. Stewart, A. R. Gerber, R. H. Byers, F. K. Lee, P. M. O'Malley, and A. J. Nahmias. 1988. Prior herpes simplex virus type 2 infection as a risk factor for HIV infection. JAMA 259:1048-1050.
19. Hook, L. M., J. M. Lubinski, M. Jiang, M. K. Pangburn, and H. M. Friedman. 2006. Herpes simplex virus type 1 and 2 glycoprotein C prevents complement-mediated neutralization induced by natural immunoglobulin M antibody. J. Virol. 80:4038-4046.
20. Hoshino, Y., S. K. Dalai, K. Wang, L. Pesnicak, T. Y. Lau, D. M. Knipe, J. I. Cohen, and S. E. Straus. 2005. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J. Virol. 79:410-418.
21. Kaushic, C., A. A. Ashkar, L. A. Reid, and K. L. Rosenthal. 2003. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J. Virol. 77:4558-4565.
22. Langenberg, A. G., L. Corey, R. L. Ashley, W. P. Leong, and S. E. Straus, for the Chiron HSV Vaccine Study Group. 1999. A prospective study of new infections with herpes simplex virus type 1 and type 2. N. Engl. J. Med. 341:1432-1438.
23. Lubinski, J., L. Wang, D. Mastellos, A. Sahu, J. D. Lambris, and H. M. Friedman. 1999. In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC. J. Exp. Med. 190:1637-1646.
24. Markert, J. M., J. N. Parker, D. J. Buchsbaum, W. E. Grizzle, G. Y. Gillespie, and R. J. Whitley. 2006. Oncolytic HSV-1 for the treatment of brain tumours. Herpes 13:66-71.
25. Meignier, B., R. Longnecker, and B. Roizman. 1988. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J. Infect. Dis. 158:602-614.
26. Meignier, B., B. Martin, R. J. Whitley, and B. Roizman. 1990. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J. Infect. Dis. 162:313-321.
27. Mercadal, C. M., M. Slaoui, S. M. Brown, and B. T. Rouse. 1993. Efficacy of the herpes simplex virus types 1 and 2 mutant viruses to confer protection against zosteriform spread in mice. Viral Immunol. 6:35-42.
28. Miriagou, V., R. Argnani, A. Kakkanas, U. Georgopoulou, R. Manservigi, and P. Mavromara. 1995. Expression of the herpes simplex virus type 1 glycoprotein E in human cells and in Escherichia coli: protection studies against lethal viral infection in mice. J. Gen. Virol. 76:3137-3143.
29. Nagashunmugam, T., J. Lubinski, L. Wang, L. T. Goldstein, B. S. Weeks, P. Sundaresan, E. H. Kang, G. Dubin, and H. M. Friedman. 1998. In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor. J. Virol. 72:5351-5359.
30. Nass, P. H., K. L. Elkins, and J. P. Weir. 1998. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins. J. Infect. Dis. 178:611-617.
31. Oxman, M. N., M. J. Levin, G. R. Johnson, K. E. Schmader, S. E. Straus, L. D. Gelb, R. D. Arbeit, M. S. Simberkoff, A. A. Gershon, L. E. Davis, A. Weinberg, K. D. Boardman, H. M. Williams, J. H. Zhang, P. N. Peduzzi, C. E. Beisel, V. A. Morrison, J. C. Guatelli, P. A. Brooks, C. A. Kauffman, C. T. Pachucki, K. M. Neuzil, R. F. Betts, P. F. Wright, M. R. Griffin, P. Brunell, N. E. Soto, A. R. Marques, S. K. Keay, R. P. Goodman, D. J. Cotton, J. W. Gnann, Jr., J. Loutit, M. Holodniy, W. A. Keitel, G. E. Crawford, S. S. Yeh, Z. Lobo, J. F. Toney, R. N. Greenberg, P. M. Keller, R. Harbecke, A. R. Hayward, M. R. Irwin, T. C. Kyriakides, C. Y. Chan, I. S. Chan, W. W. Wang, P. W. Annunziato, and J. L. Silber. 2005. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 352:2271-2284.
32. Ramachandran, S., and P. R. Kinchington. 2007. Potential prophylactic and therapeutic vaccines for HSV infections. Curr. Pharm. Des. 13:1965-1973.
33. Saldanha, C. E., J. Lubinski, C. Martin, T. Nagashunmugam, L. Wang, H. van der Keyl, R. Tal-Singer, and H. M. Friedman. 2000. Herpes simplex virus type 1 glycoprotein E domains involved in virus spread and disease. J. Virol. 74:6712-6719.
34. Smith, J. S., and N. J. Robinson. 2002. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186:S3-S28.
35. Stanberry, L. R., A. L. Cunningham, A. Mindel, L. L. Scott, S. L. Spruance, F. Y. Aoki, and C. J. Lacey. 2000. Prospects for control of herpes simplex virus disease through immunization. Clin. Infect. Dis. 30:549-566.
36. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepa-peliere, and G. Dubin, for the GlaxoSmithKline Herpes Vaccine Efficacy Study Group. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
37. Suligoi, B., M. Dorrucci, I. Uccella, M. Andreoni, and G. Rezza. 2003. Effect of multiple herpesvirus infections on the progression of HIV disease in a cohort of HIV seroconverters. J. Med. Virol. 69:182-187.
38. Thompson, R. L., and N. M. Sawtell. 2001. Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival. J. Virol. 75:6660-6675.
39. Van de Walle, G. R., H. W. Favoreel, H. J. Nauwynck, and M. B. Pensaert. 2003. Antibody-induced internalization of viral glycoproteins and gE-gI Fc receptor activity protect pseudorabies virus-infected monocytes from efficient complement-mediated lysis. J. Gen. Virol. 84:939-947.
40. Wald, A. 2006. Genital HSV-1 infections. Sex. Transm. Infect. 82:189-190.
41. Wang, F., W. Tang, H. M. McGraw, J. Bennett, L. W. Enquist, and H. M. Friedman. 2005. Herpes simplex virus type 1 glycoprotein E is required for axonal localization of capsid, tegument, and membrane glycoproteins. J. Virol. 79:13362-13372.
42. Weise, K., H. C. Kaerner, J. Glorioso, and C. H. Schroder. 1987. Replacement of glycoprotein B gene sequences in herpes simplex virus type 1 strain ANG by corresponding sequences of the strain KOS causes changes of plaque morphology and neuropathogenicity. J. Gen. Virol. 68:1909-1919.
43. Whitley, R. J., and B. Roizman. 2002. Herpes simplex viruses: is a vaccine tenable? J. Clin. Investig. 110:145-151.
44. Xu, F., M. R. Sternberg, B. J. Kottiri, G. M. McQuillan, F. K. Lee, A. J. Nahmias, S. M. Birman, and L. E. Markowitz. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964-973.